Citations (86)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (20)
Chih-Chieh Yen & Chia-Jui Yen. (2022) Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opinion on Drug Safety 21:2, pages 157-166.
Read now
Read now
Haichuan Wang, Xin Chen & Diego F. Calvisi. (2021) Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics. Expert Opinion on Therapeutic Targets 25:8, pages 645-658.
Read now
Read now
Samar Salam Qawoogha & Aliasgar Shahiwala. (2020) Identification of potential anticancer phytochemicals against colorectal cancer by structure-based docking studies. Journal of Receptors and Signal Transduction 40:1, pages 67-76.
Read now
Read now
Uqba Khan & Manish A. Shah. (2019) Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer. Expert Opinion on Biological Therapy 19:11, pages 1135-1141.
Read now
Read now
Francesca Battaglin, Alberto Puccini, Rossana Intini, Marta Schirripa, Alessandra Ferro, Francesca Bergamo, Sara Lonardi, Vittorina Zagonel, Heinz-Josef Lenz & Fotios Loupakis. (2018) The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Review of Anticancer Therapy 18:3, pages 251-266.
Read now
Read now
Oscar Arrieta, Zyanya Lucia Zatarain-Barrón, Andrés F. Cardona, Amir Carmona & Mariana Lopez-Mejia. (2017) Ramucirumab in the treatment of non-small cell lung cancer. Expert Opinion on Drug Safety 16:5, pages 637-644.
Read now
Read now
Anne Steins, Eva A. Ebbing, Marcel C. M. Pistorius, Cynthia Waasdorp, Kausilia K. Krishnadath, Jan Paul Medema, Johanna W. Wilmink, Ron A. A. Mathôt, Maarten F. Bijlsma & Hanneke W. M. van Laarhoven. (2017) Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel. Drug Delivery 24:1, pages 1801-1810.
Read now
Read now
Maryann R Cooper, Chelsea Binkowski, Jessica Hartung & Jennifer Towle. (2016) Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer. OncoTargets and Therapy 9, pages 1953-1960.
Read now
Read now
Giuseppe Aprile, Laura Ferrari, Chiara Cremolini, Francesca Bergamo, Caterina Fontanella, Francesca Battaglin, Karim Rihawi, Sara Lonardi, Fotios Loupakis & Mario Scartozzi. (2016) Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. Expert Review of Clinical Pharmacology 9:7, pages 877-885.
Read now
Read now
Asuncion Diaz-Serrano, Maria C. Riesco-Martinez & Rocio Garcia-Carbonero. (2016) The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy 16:6, pages 585-595.
Read now
Read now
Valentina Gambardella, Noelia Tarazona, Juan Miguel Cejalvo, Susana Roselló & Andrés Cervantes. (2016) Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer. Expert Opinion on Drug Metabolism & Toxicology 12:4, pages 449-456.
Read now
Read now
Lingdi Zhao, Wei Li, Huiying Zhang, Nan Hou, Lanwei Guo & Quanli Gao. (2015) Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials. OncoTargets and Therapy 8, pages 2775-2781.
Read now
Read now
Sara Pilotto, Silvia Novello, Umberto Peretti, Stefania Kinspergher, Ludovica Ciuffreda, Michele Milella, Luisa Carbognin, Tiziana Vavalà, Roberto Ferrara, Mario Caccese, Giampaolo Tortora & Emilio Bria. (2015) An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer. Expert Opinion on Investigational Drugs 24:9, pages 1143-1161.
Read now
Read now
Kohei Shitara & Atsushi Ohtsu. (2015) Ramucirumab for gastric cancer. Expert Review of Gastroenterology & Hepatology 9:2, pages 133-139.
Read now
Read now
Giuseppe Aprile, Erika Rijavec, Caterina Fontanella, Karim Rihawi & Francesco Grossi. (2014) Ramucirumab: preclinical research and clinical development. OncoTargets and Therapy 7, pages 1997-2006.
Read now
Read now
Timothy McCarthy & Bert H O’Neil. (2014) Angiogenesis inhibitors in gastric cancer. Orphan Drugs: Research and Reviews 4, pages 55-61.
Read now
Read now
Geraldine O’Sullivan Coyne & Mauricio Burotto. (2014) Clinical experience with ramucirumab: outcomes in breast cancer. Expert Opinion on Biological Therapy 14:9, pages 1351-1360.
Read now
Read now
Afsaneh Barzi & Eddie Thara. (2014) Angiogenesis in esophageal and gastric cancer: a paradigm shift in treatment. Expert Opinion on Biological Therapy 14:9, pages 1319-1332.
Read now
Read now
Bénédicte FAUVEL & Aziz Yasri. (2014) Antibodies directed against receptor tyrosine kinases. mAbs 6:4, pages 838-851.
Read now
Read now
Valentina Rossi, Rossella Martinello, Caterina Aversa & Filippo Montemurro. (2014) 2013 San Antonio Breast Cancer Symposium. Expert Opinion on Pharmacotherapy 15:8, pages 1191-1195.
Read now
Read now
Articles from other publishers (66)
Yahya Abdullah. (2023) An Overview of Current Biomarkers, the Therapeutic Implications, and the Emerging Role of hERG1 Expression in Gastric Cancer: A Literature Review. Cureus.
Crossref
Crossref
Sumeet Singh, Vinita Gouri & Mukesh Samant. (2023) TGF-β in correlation with tumor progression, immunosuppression and targeted therapy in colorectal cancer. Medical Oncology 40:11.
Crossref
Crossref
Ibrahim A. Darwish, Nourah Z. Alzoman & Nehal N. Khalil. (2023) A Novel Highly Sensitive Chemiluminescence Enzyme Immunoassay with Signal Enhancement Using Horseradish Peroxidase-Luminol-Hydrogen Peroxide Reaction for the Quantitation of Monoclonal Antibodies Used for Cancer Immunotherapy. Chemosensors 11:4, pages 245.
Crossref
Crossref
Satoru Hagiwara, Naoshi Nishida & Masatoshi Kudo. (2023) Advances in Immunotherapy for Hepatocellular Carcinoma. Cancers 15:7, pages 2070.
Crossref
Crossref
Shigeo Shimose, Rie Sugimoto, Atsushi Hiraoka, Masatoshi Tanaka, Hideki Iwamoto, Yuki Tanaka, Fujimasa Tada, Hideko Ohama, Takashi Niizeki, Tomotake Shirono, Etsuko Moriyama, Yu Noda, Naoki Kamachi, Masahito Nakano, Ryoko Kuromatsu, Hironori Koga & Takumi Kawaguchi. (2022) Significance of ramucirumab following atezolizumab plus bevacizumab therapy for hepatocellular carcinoma using real‐world data. Hepatology Research 53:2, pages 116-126.
Crossref
Crossref
Amit Dey, Abhijit Mitra, Surajit Pathak, Suhanya Prasad, Alexander Sun Zhang, Hong Zhang, Xiao-Feng Sun & Antara Banerjee. (2023) Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer. Technology in Cancer Research & Treatment 22, pages 153303382311784.
Crossref
Crossref
Andrea Cignarella, Gian Paolo Fadini, Chiara Bolego, Lucia Trevisi, Carlotta Boscaro, Viola Sanga, Teresa Maria Seccia, Antonio Rosato, Gian Paolo Rossi & Matthias Barton. (2022) Clinical efficacy and safety of angiogenesis inhibitors: sex differences and current challenges. Cardiovascular Research 118:4, pages 988-1003.
Crossref
Crossref
Sunita Dahiya & Rajiv Dahiya. 2022. Nanocarriers for Drug-Targeting Brain Tumors. Nanocarriers for Drug-Targeting Brain Tumors
299
327
.
Tomas Koltai, Stephan Joel Reshkin & Rosa Angela Cardone. 2022. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy
147
197
.
Yuxin Zhao, Haiyong Wang & Chengwei He. (2021) Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy. Journal of Cancer Research and Clinical Oncology 147:12, pages 3653-3664.
Crossref
Crossref
Yoichi Ohtaki, Kyoichi Kaira, Toshiki Yajima, Bilguun Erkhem‐Ochir, Osamu Kawashima, Mitsuhiro Kamiyoshihara, Hitoshi Igai, Ryoichi Onozato, Takashi Ibe, Takayuki Kosaka, Seshiru Nakazawa, Toshiteru Nagashima, Tetsunari Oyama & Ken Shirabe. (2021) Comprehensive expressional analysis of chemosensitivity‐related markers in large cell neuroendocrine carcinoma of the lung. Thoracic Cancer 12:20, pages 2666-2679.
Crossref
Crossref
Jin Kim, Jae-Myung Yoo, Jong-Suk Park, Jungeun Kim, Sun-Gun Kim, Young-Ju Seok, Jun-Ho Son & Hyo Kim. (2021)
Anti‑angiogenic effect of mountain ginseng
in vitro
and
in vivo
: Comparison with farm‑cultivated ginseng
. Molecular Medicine Reports 24:2.
Crossref
Crossref
Zbynek Novy, Jiri Janousek, Pavel Barta, Milos Petrik, Marian Hajduch & Frantisek Trejtnar. (2021) Preclinical evaluation of anti‐VEGFR2 monoclonal antibody ramucirumab labelled with zirconium‐89 for tumour imaging. Journal of Labelled Compounds and Radiopharmaceuticals 64:7, pages 262-270.
Crossref
Crossref
Andrew X. Zhu, Richard S. Finn, Yoon-Koo Kang, Chia-Jui Yen, Peter R. Galle, Josep M. Llovet, Eric Assenat, Giovanni Brandi, Kenta Motomura, Izumi Ohno, Bruno Daniele, Arndt Vogel, Tatsuya Yamashita, Chih-Hung Hsu, Guido Gerken, John Bilbruck, Yanzhi Hsu, Kun Liang, Ryan C. Widau, Chunxiao Wang, Paolo Abada & Masatoshi Kudo. (2021) Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. British Journal of Cancer 124:8, pages 1388-1397.
Crossref
Crossref
Kang Cheng, Chen-Fu Liu & Guo-Wu Rao. (2021) Anti-angiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors. Current Medicinal Chemistry 28:13, pages 2540-2564.
Crossref
Crossref
Hashem O. Alsaab, Alanoud S. Al-Hibs, Rami Alzhrani, Khawlah K. Alrabighi, Aljawharah Alqathama, Akram Alwithenani, Atiah H. Almalki & Yusuf S. Althobaiti. (2021) Nanomaterials for Antiangiogenic Therapies for Cancer: A Promising Tool for Personalized Medicine. International Journal of Molecular Sciences 22:4, pages 1631.
Crossref
Crossref
Kyusang Hwang, Jin Hwan Yoon, Ji Hyun Lee & Sukmook Lee. (2021) Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers. Biomedicines 9:1, pages 39.
Crossref
Crossref
Chanchal Kumar, Rajat Pratap Singh, Mrigendra Kumar Dwiwedi & Ajay Amit. 2021. Colon Cancer Diagnosis and Therapy. Colon Cancer Diagnosis and Therapy
271
308
.
Fabian Adakole Ikwu, Yusuf Isyaku, Babatunde Samuel Obadawo, Hadiza Abdulrahman Lawal & Samuel Akolade Ajibowu. (2020) In silico design and molecular docking study of CDK2 inhibitors with potent cytotoxic activity against HCT116 colorectal cancer cell line. Journal of Genetic Engineering and Biotechnology 18:1.
Crossref
Crossref
Sophie Marie Anne Effing & Bishal Gyawali. (2020) Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials. EClinicalMedicine 25, pages 100458.
Crossref
Crossref
Song Yi Ko & Honami Naora. (2020) Extracellular Vesicle Membrane-Associated Proteins: Emerging Roles in Tumor Angiogenesis and Anti-Angiogenesis Therapy Resistance. International Journal of Molecular Sciences 21:15, pages 5418.
Crossref
Crossref
Balak Das Kurmi, Preeti Patel, Rishi Paliwal & Shivani Rai Paliwal. (2020) Molecular approaches for targeted drug delivery towards cancer: A concise review with respect to nanotechnology. Journal of Drug Delivery Science and Technology 57, pages 101682.
Crossref
Crossref
Maxim Sorokin, Elena Poddubskaya, Madina Baranova, Alex Glusker, Lali Kogoniya, Ekaterina Markarova, Daria Allina, Maria Suntsova, Victor Tkachev, Andrew Garazha, Marina Sekacheva & Anton Buzdin. (2020) RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. Molecular Case Studies 6:2, pages a004945.
Crossref
Crossref
Heba T. Abdel‐Mohsen, Eman A. Abd El‐Meguid, Ahmed M. El Kerdawy, Abeer E. E. Mahmoud & Mamdouh M. Ali. (2020) Design, synthesis, and molecular docking of novel 2‐arylbenzothiazole multiangiokinase inhibitors targeting breast cancer. Archiv der Pharmazie 353:4.
Crossref
Crossref
Feng Gao & Chun Yang. (2020) Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic. Current Cancer Drug Targets 20:1, pages 3-18.
Crossref
Crossref
Man Ju, Honggang Cheng, Kai Qu & Xiangqian Lu. (2020) Efficacy and safety of ramucirumab treatment in patients with advanced colorectal cancer. Medicine 99:24, pages e20618.
Crossref
Crossref
Hiroki Tanaka, Yu Sakurai, Jessica Anindita & Hidetaka Akita. (2020) Development of lipid-like materials for RNA delivery based on intracellular environment-responsive membrane destabilization and spontaneous collapse. Advanced Drug Delivery Reviews 154-155, pages 210-226.
Crossref
Crossref
N. A. Seebacher, A. E. Stacy, G. M. Porter & A. M. Merlot. (2019) Clinical development of targeted and immune based anti-cancer therapies. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Crossref
Agnieszka Paradowska-Gorycka, Barbara Stypinska, Andrzej Pawlik, Damian Malinowski, Katarzyna Romanowska-Prochnicka, Malgorzata Manczak & Marzena Olesinska. (2019) KDR (VEGFR2) Genetic Variants and Serum Levels in Patients with Rheumatoid Arthritis. Biomolecules 9:8, pages 355.
Crossref
Crossref
Haitham AlRabiah, Mohammed A. Hamidaddin & Ibrahim A. Darwish. (2019) Automated flow fluorescent noncompetitive immunoassay for measurement of human plasma levels of monoclonal antibodies used for immunotherapy of cancers with KinExA™ 3200 biosensor. Talanta 192, pages 331-338.
Crossref
Crossref
Michelle H. Townsend, Gajendra Shrestha, Richard A. Robison & Kim L. O’Neill. (2018) The expansion of targetable biomarkers for CAR T cell therapy. Journal of Experimental & Clinical Cancer Research 37:1.
Crossref
Crossref
Lucia De Rosa, Rossella Di Stasi & Luca Domenico D'Andrea. (2018) Pro-angiogenic peptides in biomedicine. Archives of Biochemistry and Biophysics 660, pages 72-86.
Crossref
Crossref
Mohammed A. Hamidaddin, Haitham AlRabiah & Ibrahim A. Darwish. (2018) Development and validation of generic heterogeneous fluoroimmunoassay for bioanalysis of bevacizumab and cetuximab monoclonal antibodies used for cancer immunotherapy. Talanta 188, pages 562-569.
Crossref
Crossref
Jean-Luc Raoul, Masatoshi Kudo, Richard S. Finn, Julien Edeline, Maria Reig & Peter R. Galle. (2018) Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treatment Reviews 68, pages 16-24.
Crossref
Crossref
Min Li, Fangrong Zhang, Yujie Su, Jianping Zhou & Wei Wang. (2018) Nanoparticles designed to regulate tumor microenvironment for cancer therapy. Life Sciences 201, pages 37-44.
Crossref
Crossref
Mostafa M. Ghorab, Fatma A. Ragab, Helmy I. Heiba, Marwa G. El-Gazzar & Mostafa G.M. El-Gazzar. (2018) Novel thioureido-benzenesulfonamide derivatives with enaminone linker as potent anticancer, radiosensitizers and VEGFR2 inhibitors. Bioorganic & Medicinal Chemistry Letters 28:9, pages 1464-1470.
Crossref
Crossref
Guanying Hu, Peng Yang, Yu Zeng, Sanyin Zhang & Jiage Song. (2018) Danggui Buxue decoction promotes angiogenesis by up-regulation of VEGFR1/2 expressions and down-regulation of sVEGFR1/2 expression in myocardial infarction rat. Journal of the Chinese Medical Association 81:1, pages 37-46.
Crossref
Crossref
Paul A. Moore, Ross La Motte‐Mohs, Jonathan C. Li & Gurunadh R. Chichili. 2017. Protein Therapeutics. Protein Therapeutics
521
585
.
A Vennepureddy, P Singh, R Rastogi, JP Atallah & T Terjanian. (2016) Evolution of ramucirumab in the treatment of cancer – A review of literature. Journal of Oncology Pharmacy Practice 23:7, pages 525-539.
Crossref
Crossref
Yi-Yong Baek, Dong-Keon Lee, Joohwan Kim, Ji-Hee Kim, Wonjin Park, Taesam Kim, Sanghwa Han, Dooil Jeoung, Ji Chang You, Hansoo Lee, Moo-Ho Won, Kwon-Soo Ha, Young-Guen Kwon & Young-Myeong Kim. (2016) Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism. Oncotarget 8:7, pages 11763-11777.
Crossref
Crossref
Kevin Brown Chandler, Deborah R. Leon, Rosana D. Meyer, Nader Rahimi & Catherine E. Costello. (2016)
Site-Specific
N
-Glycosylation of Endothelial Cell Receptor Tyrosine Kinase VEGFR-2
. Journal of Proteome Research 16:2, pages 677-688.
Crossref
Crossref
Chen Lin, Zaizhong Zhang, Yun Xu, Ruohan Wang, Shaoquan Chen, Jian Gao, Daiyong Wang, Qiaojia Huang, Xiaohuang Tu & Lie Wang. (2016) High Tumor Vascular Endothelial Growth Factor Expression Is Associated With Poorer Clinical Outcomes in Resected T3 Gastric Adenocarcinoma. American Journal of Clinical Pathology 146:3, pages 278-288.
Crossref
Crossref
Beverly L. Falcon, Sudhakar Chintharlapalli, Mark T. Uhlik & Bronislaw Pytowski. (2016) Antagonist antibodies to vascular endothelial growth factor receptor 2 (VEGFR-2) as anti-angiogenic agents. Pharmacology & Therapeutics 164, pages 204-225.
Crossref
Crossref
Florian Lordick & Yelena Y. Janjigian. (2016) Clinical impact of tumour biology in the management of gastroesophageal cancer. Nature Reviews Clinical Oncology 13:6, pages 348-360.
Crossref
Crossref
Seung Tae Kim, Soomin Ahn, Jeeyun Lee, Su Jin Lee, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Kyoung-Mee Kim & Joon Oh Park. (2016) Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). Journal of Cancer Research and Clinical Oncology 142:6, pages 1231-1237.
Crossref
Crossref
Hyeong Sim Choi, Min Kyoung Kim, Kangwook Lee, Kang Min Lee, Youn Kyung Choi, Yong Cheol Shin, Sung-Gook Cho & Seong-Gyu Ko. (2016) SH003 represses tumor angiogenesis by blocking VEGF binding to VEGFR2. Oncotarget 7:22, pages 32969-32979.
Crossref
Crossref
Sile Chen, Xinhua Zhang, Jianjun Peng, Ertao Zhai, Yulong He, Hui Wu, Chuangqi Chen, Jinping Ma, Zhao Wang & Shirong Cai. (2016) VEGF promotes gastric cancer development by upregulating CRMP4. Oncotarget 7:13, pages 17074-17086.
Crossref
Crossref
Mei Lv, Yan-fei Xia, Bo Li, Hui Liu, Jin-yu Pan, Bei-bei Li, Cheng Zhang & Feng-shuang An. (2015) Serum amyloid A stimulates vascular endothelial growth factor receptor 2 expression and angiogenesis. Journal of Physiology and Biochemistry 72:1, pages 71-81.
Crossref
Crossref
Haiming Luo, Christopher G. England, Stephen A. Graves, Haiyan Sun, Glenn Liu, Robert J. Nickles & Weibo Cai. (2016)
PET Imaging of VEGFR-2 Expression in Lung Cancer with
64
Cu-Labeled Ramucirumab
. Journal of Nuclear Medicine 57:2, pages 285-290.
Crossref
Crossref
I. I. Turnaev, D. A. Rasskazov, O. V. Arkova, M. P. Ponomarenko, P. M. Ponomarenko, L. K. Savinkova & N. A. Kolchanov. (2016) Hypothetical SNP markers that significantly affect the affinity of the TATA-binding protein to VEGFA, ERBB2, IGF1R, FLT1, KDR, and MET oncogene promoters as chemotherapy targets. Molecular Biology 50:1, pages 141-152.
Crossref
Crossref
Kai Wang, Xiao Qu, Ying Wang, Wei Dong, Hongchang Shen, Tiehong Zhang, Yang Ni, Qi Liu & Jiajun Du. (2015) The Impact of Ramucirumab on Survival in Patients with Advanced Solid Tumors: A Systematic Review and Meta-Analysis of Randomized II/III Controlled Trials. Clinical Drug Investigation 36:1, pages 27-39.
Crossref
Crossref
Brian A. BaldoBrian A. Baldo. 2016. Safety of Biologics Therapy. Safety of Biologics Therapy
57
140
.
Gayle Smythe. 2016. Growth Factors and Cytokines in Skeletal Muscle Development, Growth, Regeneration and Disease. Growth Factors and Cytokines in Skeletal Muscle Development, Growth, Regeneration and Disease
161
183
.
Tao ZhaoJie ZhangYanyan ZhangJingjing HuangXin WangYingqian ZhangMing ZhangYe YuanKai XiaoHongxia LiZhihui Zhong. (2015)
Vascular Endothelial Growth Factor Receptor 2 Antibody, BC001, Attenuates Laser-Induced Choroidal Neovascularization in Rhesus Monkeys (
Macaca mulatta
)
. Journal of Ocular Pharmacology and Therapeutics 31:10, pages 611-616.
Crossref
Crossref
Vincenzo Ricci, Monica Ronzoni & Teresa Fabozzi. (2015) Aflibercept a new target therapy in cancer treatment: a review. Critical Reviews in Oncology/Hematology 96:3, pages 569-576.
Crossref
Crossref
Janghee Woo, Stacey A. Cohen & Jonathan E. Grim. (2015) Targeted therapy in gastroesophageal cancers: past, present and future: Figure 1.. Gastroenterology Report, pages gov052.
Crossref
Crossref
E.G. Chiorean, H.I. Hurwitz, R.B. Cohen, J.D. Schwartz, R.P. Dalal, F.E. Fox, L. Gao & C.J. Sweeney. (2015) Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Annals of Oncology 26:6, pages 1230-1237.
Crossref
Crossref
Niels Reinmuth, David Heigener & Martin Reck. (2015) Novel angiogenesis inhibitors in nonsmall cell lung cancer. Current Opinion in Oncology 27:2, pages 79-86.
Crossref
Crossref
Yihai Cao. (2014) VEGF-targeted cancer therapeutics—paradoxical effects in endocrine organs. Nature Reviews Endocrinology 10:9, pages 530-539.
Crossref
Crossref
Raewyn M. Poole & Asha Vaidya. (2014) Ramucirumab: First Global Approval. Drugs 74:9, pages 1047-1058.
Crossref
Crossref
James R. W. Conway, Neil O. Carragher & Paul Timpson. (2014) Developments in preclinical cancer imaging: innovating the discovery of therapeutics. Nature Reviews Cancer 14:5, pages 314-328.
Crossref
Crossref
Sandro De Falco. (2014) Antiangiogenesis therapy: an update after the first decade. The Korean Journal of Internal Medicine 29:1, pages 1.
Crossref
Crossref
X‐Y Zhang, MR Birtwistle & JM Gallo. (2014) A General Network Pharmacodynamic Model–Based Design Pipeline for Customized Cancer Therapy Applied to the VEGFR Pathway. CPT: Pharmacometrics & Systems Pharmacology 3:1, pages 1-9.
Crossref
Crossref
Xing-Wang Zhao, Dan Liu, Sheng-Lin Luan, Guo-Dong Hu, Jin-Ling Lv, Yong-Kui Jing & Lin-Xiang Zhao. (2013) Synthesis and biological evaluation of substituted 1,2,3-benzotriazines and pyrido[3,2-d]-1,2,3-triazines as inhibitors of vascular endothelial growth factor receptor-2. Bioorganic & Medicinal Chemistry 21:24, pages 7807-7815.
Crossref
Crossref
Giuseppe Aprile, Marta Bonotto, Elena Ongaro, Carmelo Pozzo & Francesco Giuliani. (2013) Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use. Drugs 73:18, pages 2003-2015.
Crossref
Crossref
Yohei Mukai & Shinsaku Nakagawa. (2013) Drug delivery into the tumor vasculature with the cell-internalizing monoclonal antibody. Drug Delivery System 28:5, pages 430-438.
Crossref
Crossref